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CD14, a co-receptor for endotoxin, plays a significant role in regulating the inflammatory
response to this agent. The C-159T single nucleotide polymorphism (SNP) in the CD14 gene
promoter is an important regulator of CD14 expression, with TT homozygotes having increased
expression of CD14. This SNP has been linked to pathogenesis of asthma and with cardiovas-
cular diseases in smokers. We hypothesize that CD14 also plays a role in the pathophysiology
of COPD in smokers who are exposed to endotoxin contained in cigarette smoke as well as
endotoxin derived from Gram-negative microbes colonizing their airways. To assess the effect
of the C-159T SNP of the CD14 gene promoter on lung function, we recruited 246 smokers 40
years of age or older with a range of 10e156 pack-year smoking exposures. The TT genotype
was associated with lower lung function in smokers with a moderate smoking history. However,
the CC genotype was associated with decreased lung function in heavy smokers (>56 pack
years). The effect of CC genotype on severity of COPD is analogous with the effect of this geno-
type in risk for asthma. CD14 may be a factor in the pathophysiology of COPD, as it is in asthma
and smoking-related cardiovascular diseases.
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Exposure to environmental endotoxin is an important factor
in the development of a variety of airway diseases,
including asthma and occupational lung disease. Endotoxin
binds with CD14, a glycosylphosphatidylinositol-linked.
Influence of C-159T SNP of the CD14 gene promoter on lung function in smokers 1359plasma-membrane glycoprotein which is abundantly
expressed on monocytic cells and facilitates endotoxin
ligation of TLR4/MD2 with ultimate activation of NF-kB.1,2
CD14 expression on airway monocytes and macrophages is
an important determinant of airway responses to inhaled
endotoxin, as shown in CD14/C57Bl6 mice3 and demon-
strated for human subjects in our report that the degree of
neutrophil influx to the airway after endotoxin challenge
correlated with CD14 expression on airway macrophages
prior to challenge.4 In both ex-smokers and current smokers
Domagala-Kulawik et al.5 reported an inverse correlation
between the proportion of sputum macrophages expressing
mCD14 and the % predicted FVC.
Though the role of endotoxin exposure and CD14 has
been extensively studied in other airways diseases, it has
not been extensively studied in COPD associated with
smoking. Recently, Regueiro et al.6 reported that sCD14
levels are markedly increased in bronchoalveolar lavage
fluid in smokers with normal lung function and COPD
patients (regardless of smoking status). Endotoxin is
a significant constituent of tobacco smoke,7 and ambient
air endotoxin is markedly increased in environments which
include tobacco smoke.8 Additionally, the airways of many
smokers are infected or colonized with gram-negative
bacteria, providing an endogenous source of endotoxin
exposure to airway macrophages and monocytes.9 Given
the exposure of smokers to endotoxin in the airway, we
surmised that CD14 modulates the severity of COPD.
In asthma,10 occupational lung disease,11 and post-lung
transplant,12 the commonly occurring C-159T polymorphism
(also referred to as C-260T) of the CD14 gene promoter has
been shown to be an important genetic modifier of airway
disease. However, the possible effects of this polymorphism
do not appear to have been examined in regard to the
susceptibility of smokers to development of COPD. The T
allele of this SNP is associated with increased production of
CD14, and persons with the TT genotype would be expected
to be more responsive to endotoxin. As compared to the CC
and CT genotypes, the TT genotype for the CD14 gene
promoter has been associatedwith increased serum levels of
soluble CD1413 and increased response of PBMC from asth-
matic children to endotoxin in vitro.14 The T allele is linked
to lower forced expiratory flow rates in never-smoker
farmers,11 to the protective effect of endotoxin exposure in
decreasing risk for developing allergy and asthma, and to the
risk of acute exacerbation of airway disease associated with
high levels of environmental endotoxin.1,15e17
Tobacco smoke exposure also impacts gene/environment
interactions in asthma. Genome wide scans have shown that
in children passively exposed to tobacco smoke, there is
linkage between asthma and bronchial hyper-responsiveness
and chromosome 5q, the location of the CD14 gene.18 In
Latino populations, CD14 SNPs were linked with asthma
severity and IgE production in persons exposed to tobacco
smoke.19 Women also demonstrated an association between
the CD14 C-260T genotype and total IgE levels that was
modified by the level of endotoxin exposure, such that
compared with CC and CT genotypes, the TT genotype was
associated with lower serum IgE in individuals with very low
environmental endotoxin exposure, but with higher serum
IgE in individuals with higher endotoxin exposure.20 Tobacco
smoke exposure has also been shown to increase serumlevels of soluble CD14 in children.21 Though there are con-
flicting reports of the role of CD14 in cardiovascular disease
(see review by Arroyo-Espliguoro et al.22), CD14 has been
implicated as a risk factor for myocardial infarction, stroke,
and cardiovascular diseases with greater risk being reported
in smokers carrying the T allele.23e25 Taken together, these
observations suggest that CD14 may be an important bio-
logical factor in mediating the pathophysiology of diseases
linked to tobacco smoke exposure.
We hypothesized that CD14 is a determinant of COPD
disease severity regarding airway obstruction associated with
tobacco smoking. To explore this hypothesis, we assessed the
role of the C-159T SNP of the CD14 gene promoter on lung
function in 246 smokers identified as having COPDwhowereat
least 40 years of age with at least a 10 pack-year history of
tobacco use. As the TT genotype is associated with increased
expression of CD14, our a priori hypothesis was that COPD
patients who were homozygous for the T allele at the C-159T
polymorphismwould have decreased lung function relative to
those with CT or CC genotypes. To our knowledge, this is the
first report examining the effect of the CD14 gene promoter
on lung function of smokers with COPD.Methods
Subjects
Volunteers were identified via response to advertisements
and recruitment from clinical research sites in Chapel Hill
and Raleigh, NC. Written consent was obtained. To be
included in this study, volunteers needed to be >40 years of
age, have a smoking history of at least 10 pack years, and
meet one of the following criteria which suggest an adverse
heath effect of smoking: FEV1< 80% of predicted, FEV/FVC
ratio of <0.75, or symptoms of chronic cough and sputum
production. Volunteers were excluded if they had other
diseases that would likely affect lung function (e.g., active
asthma, autoimmune diseases, immunodeficiencies).
Volunteers consented to collection of DNA for genotyping
using buccal swab techniques or blood collection of
lymphocytes if significant oral pathology was observed. This
study was reviewed and approved by the UNC Committee
for the Protection of the Rights of Human Subjects (IRB).
Study endpoints
Spirometry measures included the forced vital capacity
(FVC), the forced expiratory volume at one second (FEV1),
and the FEV1/FVC ratio. The FEV1 and FVCwere expressed as
the % of predicted normal values developed by Knudson
et al., accounting for gender, ethnicity, height, weight and
age.26 GOLD staging was done, with spirometric parameters
being determined after use of inhaled albuterol. Genotyping
for the C-159T polymorphism of the CD14 gene promoter was
performed as previously described.4,13
Statistical analysis
The primary hypothesis of this study was that smokers with
COPD with the TT genotype for the C-159T single nucleotide
1360 H. Zhou et al.polymorphism of the CD14 gene promoter would have
decreased lung function and increased GOLD scores relative
to those with the CT and CC genotypes. To explore the
potential effect of gene/environment interaction of smoking
in COPD, we conducted a formal statistical investigation of
the potential interaction using multiple-regression tech-
niques.27 In particular, a linear regressionmodelwas fitted for
quantitative endpoints FEV1 (% predicted), FVC (% predicted),
FEV1/FVC ratio, and a logistic regression model was fitted for
the GOLD scores (0 for non-COPD, and 1 for GOLD 1e4). All
analyses were conducted with adjustment for subject’s
current smoking status, Age, Gender (MaleZ 1, FemaleZ 0),
BMI and Race. Because there are three genotypes to consider
(TT, CT, CC),weused two dummy variables tomodel the CD14
genotype (CC as the reference group). We centered the pack-
year history variable in all regression analyses.
We built a sequence of nested models starting with a full
model that includes nonlinear terms of smoking history
(using the spline technique), genotype, interaction terms
between these two factors, and the adjustment factors
noted above. We then sequentially reduced the full model
using the maximum likelihood ratio test as model selection
criteria to arrive at the final model. The final models with
quadratic terms of pack-year history are not statistically
different from models using the spline fitting. All analyses
were carried out using the SAS version 9.1 (SAS Institute
Inc., Cary, NC).28 Analyses to test for interaction between
genotype and pack-year history were also carried out for
distinct sub-groups which represented a sizable fraction of
the total study cohort, including current smokers, ex-
smokers and Caucasians.
Results
General findings
246 volunteers were recruited and genotyped, and under-
went spirometric and clinical evaluation. The demographic
characteristics of the entire volunteer group, as well asTable 1 Demographics and characteristics of study participant
All individuals
(nZ 246)
CD14 C-159T genotype (%) e
Age, mean SD 53.9 8.9
Male Gender (%) 54.1 (133/246)
Caucasian (%) 83.7 (206/246)
BMI, mean SD 28.2 5.8
Pack Year, mean SD 45.1 26.3
Current smokers (%) 65.0 (160/246)
Former Smokers (%) 35.0 (85/246)
FEV1 (% predicted), mean SD 76.0 27.5
FVC (% predicted), mean SD 92.1 21.4
FEV1/FVC ratio, mean SD 0.66 0.16
Gold Score (%)
1 11.8 (29/246)
2 15.0 (37/246)
3 14.2 (35/246)
4 6.5 (16/246)COPD characterization stratified on the basis of genotype
for the C-159T SNP for the CD14 gene promoter are shown
in Tables 1 and 2. Although there were no statistically
significant differences observed between the means of the
COPD outcomes (FEV1 % predicted, FVC % predicted, FEV1/
FVC ratio) across the three genotype groups, the TT group
appears to have a lower mean FEV1 (% predicted), lower
proportion of males, and lower mean FVC (% predicted),
coupled with a higher proportion of Caucasians and a lower
mean pack-year history, than the CC and CT groups. These
observations suggested that these factors should be
accounted for in the formal analysis and that an interaction
effect may exist. Not unexpectedly, there were strong
correlations between pack-year history and the % of pre-
dicted FEV1 (rZ0.43, p< 0.0001), % of predicted FVC
(r0.38, p< 0.0001), the FEV1/FVC ratio (rZ0.35,
pZ < 0.0001). When segregated on the basis of genotype,
these correlations for the CC and CT genotypes were similar
to those for the overall group, whereas those for the TT
genotype were not statistically significant.
Stratified by genotypes, the distributions for FEV1, FVC,
FEV1/FVC per pack-year quartile are depicted in Fig. 1. In
the first quartile, there was no difference in any of the
spirometric endpoints between the three genotype groups.
In the second quartile, the TT and CT groups had decreased
lung function while the CC group held steady (unadjusted p-
values are pZ 0.004 for FVC and pZ 0.026 for FEV1). In the
third quartile the TT group continued to decrease while the
CC group increased toward the CT group (unadjusted p-
values are pZ 0.015 for FVC and pZ 0.045 for FEV1).
Finally, in the upper pack-year quartile, the CC genotype
group exhibited the greatest decrease in lung function
while the TT group held steady (pZ 0.033 for FEV1/FVC
ratio, unadjusted). Considering that the pack-year history
ranged from 10 to 153, we hypothesized that there may be
a gene-by-environment (CD14 gene promoter vs. pack-year
history) effect on lung function in this cohort of COPD
patients. To investigate this possibility, we employed
a multiple-regression model to formally test the potential
interaction.s stratified by the CD14 C-159T genotype information.
Genotype CC
(nZ 78)
Genotype CT
(nZ 118)
Genotype TT
(nZ 50)
31.7 (78/246) 48.0 (118/246) 20.3 (50/246)
54.6 9.1 53.1 8.7 54.8 9.0
64.1 (50/78) 49.6 (58/118) 50.0 (25/50)
79.5 (62/78) 82.2 (97/118) 93.9 (46/49)
27.3 5.0 28.6 6.3 28.6 5.8
46.8 29.7 45.8 25.7 41.2 21.5
30.8 (49/160) 50.3 (80/160) 18.9 (30/160)
34.1 (29/85) 43.5 (37/85) 22.4 (19/85)
76.1 29.0 76.7 27.8 74.0 24.6
91.7 22.6 94.3 20.7 87.3 21.0
0.66 0.17 0.65 0.16 0.66 0.15
31.0 (9/29) 62.1 (18/29) 6.9 (2/29)
16.2 (6/37) 54.1 (20/37) 29.7 (11/37)
37.1 (13/35) 40.0 (14/35) 22.9 (8/35)
43.8 (7/16) 43.8 (7/16) 12.5 (2/16)
Table 2 Fitted regression model for the association
between pack yr, genotypes and the FEV1/FVC ratio (Full
data adjusted analysis).
Parameter Estimate Standard Error p-value
Intercept 0.7541 0.0790 <.0001
TT 0.0019 0.0245 0.938
CT 0.0235 0.0196 0.231
Pack_yr 0.0034 0.0007 <.0001
Pack_yr_sq 0.00002 0.00001 0.013
Pack_yrTT 0.0022 0.0010 0.030
Pack_yrCT 0.0016 0.0007 0.022
Current_smokers 0.0417 0.0183 0.024
Age 0.0043 0.0011 <.0001
Gender 0.0316 0.0176 0.073
Caucasian 0.0706 0.0238 0.003
BMI 0.0064 0.0015 <.0001
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Interaction of tobacco exposure and genotype on %
predicted FEV1
To determine if there is any interaction between pack-year
history and genotype on % predicted FEV1, we built
a sequence of nested regression models that include the●
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Figure 1 Box plots across four quartiles of pack-year history, by g
FVC ratio levels. Quartiles of the pack-year history are defined as 10
38e56 pack yr for Q3 and 56e153 pack yr for Q4.interaction effects and used the maximum likelihood ratio
test for testing, adjusting for age, gender, race, current
smoking status, and BMI. Although we confirmed there is
a nonlinear relationship between % predicted FEV1 and
pack-year history, we did not find a statistically significant
interaction for the CD14 genotype and smoking.
Interaction of tobacco exposure and genotype on % of
predicted FVC
The same modeling strategy for assessing the interaction
between pack-year history and genotype on % of predicted
FEV1 and FEV1/FVC ratio was employed, adjusting for age,
gender, race, current smoking status, and BMI. As for FEV1,
pack-year history was negatively associated with % of
predicted FVC (bZ0.223, p< 0.0001), with no significant
effect of CD14 genotype on the relationship between pack-
year history and FVC.
Interaction of tobacco exposure and genotype on
FEV1/FVC ratio
To assess the interaction between pack-year history and
genotype on the FEV1/FVC ratio, we employed the same
statistical strategy described for FEV1 to arrive at the final
model for FEV1/FVC ratio. The final model included
a nonlinear pack-year term. We observed a significant
interaction between the CD14 genotype and the effect ofPack Year
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e28 pack yr smoking for 1st quartile (Q1); 28e38 pack yr for Q2;
1362 H. Zhou et al.smoking history on FEV1/FVC ratio. The p-value for testing
the interactions between pack-year genotype, based on 2
degrees of freedom (for testing TT and CT vs. CC), is
pZ 0.03. CC genotype individuals have significantly and
progressively decreasing FEV1/FVC ratio with increasing
pack-year history, whereas the CT and TT genotypes
appeared to reduce the impact of pack years of smoking on
lung function. The fitted interaction between genotype and
pack-year history is illustrated in Fig. 2 where the associ-
ation between FEV1/FVC ratio and pack-year is clearly
depicted across different genotypes for a white male with
mean age (53.9) and mean BMI (28.2).
Other significant factors are subject’s age (bZ0.0043,
p< .0001), Male gender (bZ0.032, pZ 0.073), Cauca-
sian race (bZ0.071, pZ 0.003), current smoking status
(bZ 0.042, p< .024), and BMI (bZ 0.0064, p< .0001).
These findings are shown in Table 2. The FEV1/FVC ratio is
0.042 units higher in current smokers than in ex-smokers.
This might reflect the higher age of the ex-smokers as well
as the possible increased motivation to stop smoking among
more impaired smokers. As expected, older individuals
have a reduced FEV1/FVC ratio (0.043 units per 10 years).
BMI and gender appear to be significantly related to the
FEV1/FVC ratio such that higher BMI is associated with
increased FEV1/FVC ratio (0.064 units for a 10 units
increase in BMI) while men have a lower FEV1/FVC ratio
(0.032 units) as compared with women.
Interaction of tobacco exposure and genotype on GOLD
score
To model the effect of tobacco exposure and genotype on
GOLD score, GOLD stages of 1 or 2 were assigned a value of
0 and GOLD stages of 3 or 4 were assigned a value of 1.
Logistic regression analysis was then employed to evaluate
the effect of these factors and their interactions on the
GOLD outcome. Adjusting for Age, Race, Gender and BMI,
no significant effect of pack-year history or the smoking by
genotype interaction on GOLD score was observed. We also
compared GOLD stage 1e4 (classified as 1) vs. all the others
(classified as 0) and found that there is a quadratic rela-
tionship between the COPD response and the pack-year20 40 60 8
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Figure 2 Adjusted association between CD14 genotypes and lun
figures are the fitted relationship, adjusting for Age, Race, Gende
different genotypes. The graphs shown are based on a white malehistory but there is no significant gene by smoking inter-
action. Again, all analyses were adjusted for the same
factors mentioned before.
Subpopulation analysis
Recognizing that the majority of the study population is
Caucasian (83.7%) and that the Caucasian proportion in the
three genotypes is not the same (Table 1), the interaction
effects observed in the full data set may in some way
reflect a possible interaction between race and smoking
effect, we repeated the above analyses for the Caucasian
subpopulation. These analyses, adjusted for age, gender,
current smoking status, and BMI, yielded almost the same
results as the full data set for FEV1% predicted, FEV1/FVC
ratio and GOLD score.
The same statistical strategy was employed in analysis of
the ex-smoker subpopulation (nZ 85, w35% of total pop-
ulation). In this subgroup, adjusted for age, gender, and
BMI, we found a marginally significant interaction between
the pack-year history and genotype on % predicted FEV1 as
well as on FEV1/FVC ratio. The basic findings for FEV1/FVC
ratio in the ex-smokers are similar to that of the full data
set. The p-value for testing the interaction between the
pack-year and genotype (TT vs. CC) was 0.03 while the p-
value for testing the interaction for TT and CT vs. CC was
0.055 for the FEV1/FVC ratio. The final fitted models were
given in Table 3. For the FEV1 % predicted, the ex-smoker
population exhibits a much stronger, borderline statistically
significant interaction between the genotype and pack-year
history (pZ 0.054 for testing TT and CT vs. CC). The final
fitted models were given in Table 3. There is no significant
interaction for the GOLD score analysis.
From the current smoker (nZ 160) subpopulation anal-
ysis, there is still a nonlinear relationship between both the
% predicted FEV1 and the FEV1/FVC ratio, however, our
adjusted analysis based on the current smoker subpopula-
tion reveals no interaction between genotypes and pack-
year history for the FEV1/FVC ratio and the % predicted
FEV1. There are also no significant interactions for the
GOLD score analysis.0 100 120 140
k Year
Data TT
Data CT
Data CC
TT
CT
CC
g function for FEV1/FVC ratio (Full data set). The lines in the
r, and BMI, between the pack-year and FEV1/FVC ratio across
with mean Age and BMI.
Table 3 Fitted regression model for the association between pack yr, CD14 genotypes and lung function (Ex-smoker adjusted
Analysis).
Predictor Variables Fitted model for FEV1 (% predicted) Fitted model for FEV1/FVC Ratio
Parameter Estimate Standard Error P-value Parameter Estimate Standard Error P-value
Intercept 101.168 23.586 <.0001 0.615 0.144 <.0001
Pack Year 0.813 0.173 <.0001 0.005 0.001 <.0001
CD14 C-159T genotype TT 6.028 6.176 0.332 0.015 0.038 0.701
CD14 C-159T genotype CT 0.016 5.252 0.998 0.029 0.032 0.368
Pack Yr TT 0.450 0.231 0.055 0.003 0.001 0.034
Pack Yr CT 0.113 0.180 0.531 0.0003 0.001 0.762
Pack Yr2 0.009 0.003 0.001 4.2E5 1.5E5 0.007
Age 0.689 0.300 0.025 0.004 0.002 0.039
Male 5.867 4.891 0.234 0.062 0.030 0.043
Caucasian 9.206 7.769 0.240 0.091 0.048 0.060
BMI 0.552 0.509 0.282 0.011 0.003 0.0004
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In this study, we tested the hypothesis that smokers who
also had the TT genotype for the C-159T nucleotide poly-
morphism for the CD14 gene promoter would have greater
obstructive impairment of lung function (FEV1, FEV1/FVC
ratio) and increased disease severity (GOLD score) relative
to those with the CC or CT genotypes. This hypothesis was
developed on the basis of observations in asthma,17 occu-
pational lung disease11 and studies of acute response to
endotoxin challenges in normal volunteers and asth-
matics.4,29 In farmers occupationally exposed to endotoxin-
containing bioaerosols, the TT genotype was associated
with decreased lung function, including % predicted FEV1.
11
Regarding endotoxin, we have reported that the acute
airways inflammatory response to inhaled low-dose endo-
toxin is correlated positively with the pre-challenge or
constitutive level of expression of mCD14 on airway
macrophages.4
When stratifying the population only on the basis of
genotype, without accounting for smoking history or other
demographic features (such as gender, ethnicity, age), we
observed no difference in lung function of smokers with
COPD on the basis of genotype. However, given the gene-
by-environment interactions described for the severity of
allergic airway disease for the C-159T nucleotide poly-
morphism for the CD14 gene promoter relative to environ-
mental endotoxin exposure and the increased exposure of
smokers to inhaled endotoxins, it seemed plausible that
genetically based differences in lung function due to
smoking might emerge if the environmental exposure
(pack-year history) were considered.
To more completely describe and investigate the rela-
tionship between pack-year history and lung function in
persons with different genotypes for the C-159T SNP for the
CD14 gene promoter, we employed regression modeling
approaches which would take into account the demographic
features across a continuous pack-year smoking history
measure. These analyses indicate that at lower pack-year
smoking histories the TT genotype is associated with
increased risk for decreased lung function (FEV1/FVC ratio).
However, among smokers with higher pack-year histories,
the CC genotype confers greater risk. Recent studies of theacute effect of bronchodilator inhalation on forced expira-
tion in COPD have drawn attention to the phenomenon of
‘‘FVC responders’’30e33 in whom a paradoxical reduction of
FEV1/FVC ratio can occur.
32,33 These reports suggest that the
post-bronchodilator FEV1/FVC ratio (vs. % predicted FEV1) is
an appropriate parameter to employ in examining the effect
of the CD14 C-159T polymorphism on smoking-induced
decrements in lung function in our population of smokers.
Overall, these data indicate that a complex gene-by-envi-
ronment interaction of the CD14 gene promoter and lung
function operates in smokers with COPD.
While our results are partially consistent with our
hypothesis in that persons with the TT genotype appear
initially more susceptible to the effect of smoking on lung
function, the CC genotype seems to have a deleterious
effect at higher pack-year exposures. However, smoking
itself has been reported to modulate expression of CD14 on
airway macrophages irrespective of CD14 genotypes.
Smoking may also modify the effect of a given genotype on
production of soluble CD14. In a study examining serum
levels of soluble CD14 (sCD14), the T allele was associated
with increased levels of sCD14, though this was not
observed in smokers, suggesting that the effect of the T
allele on CD14 production is muted in smokers.25 In asthma,
smoking also influences the effect of the CD14 gene
promoter in disease and development of IgE responses, and
airway hyperreactivity and asthma has been linked to the
chromosome 5q region (which contains the CD14 gene).18
Also, the effect of the T allele of the CD14 gene promoter
on likelihood for developing antigen-specific IgE responses
was more pronounced in smokers.34 Thus, while the effect
of smoking on CD14 expression and the genetic regulation
of such expression is incompletely understood, it seems
likely that smoking modifies the effect of the C-159T SNP on
CD14 expression.
As noted previously, at higher pack-year exposures the
CC genotype appears to confer increased risk for impair-
ment of lung function relative to the TT genotype. This
would be consistent with the effect of the CC genotype on
risk for disease in asthma, as shown by genotype-specific
increases in both development of antigen-specific IgE
responses and wheeze in non-atopic individuals.15,19 The CC
genotype is also a risk factor for smoking-related
1364 H. Zhou et al.non-respiratory diseases. In examining the effect of
smoking on carotid atherosclerosis, those with the CC
genotype had increased risk of diseased carotids. In that
study, the authors speculated that this was due to
decreased levels of sCD14 in the serum of these
patients.35,36 As with the studies of CD14 genotype effects
on carotid artery disease, our study is limited because we
did not assess either serum or airway levels of sCD14, or
CD14 expression on airway or circulating monocytes or
macrophages from our volunteers. Thus we did not examine
the CD14 expression phenotype relative to the C-159T SNP
for the CD14 gene promoter in these smokers.
To our knowledge, this is the first examination of the
effect of the C-159T SNP of the CD14 gene promoter on the
relation between pack years of smoking and lung function,
which appears to involve a complex gene-by-environment
interaction. Our findings suggest that there is a complex
gene-by-environment interaction for the effect of the CD14
gene promoter on smoking-induced changes in lung func-
tion. The TT genotype appears to be associated with
increased risk for obstructive impairment with moderate
degrees of smoking (29e57 pack years), whereas the CC
genotype is associated with increased risk for loss of lung
function with heavy smoking (>57 pack years). While the
molecular mechanisms which mediate this effect are
unknown, our results suggest that innate immune mecha-
nisms may play an significant role in disease modulation in
smoking-induced airway obstruction in persons with COPD.
These data are also consistent with the idea that tobacco
smoke exposure may be able to modify a number of gene/
environment interactions in airway diseases. These results
provide a strong rationale for including the C-159T SNP of
the CD14 gene promoter among other candidate poly-
morphisms when studying the genetics of lung disease
related to smoking or to inhalation of endotoxin.
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